All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase,IgA proteases
Therapeutic Area: Immunology Product Name: SEL-212
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020
Details:
The companies have entered into a Research License and Option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ImmCelz
Therapeutic Area: Immunology Product Name: ImmCelz
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
ImmCelz® utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. Creative Medical Technology conducted studies showed efficacy of its ImmCelz® immunotherapy product in the collage induced model of rheumatoid arthritis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CEL-4000
Therapeutic Area: Immunology Product Name: CEL-4000
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
CEL-SCI’s LEAPS technology relates to peptide constructs which may be useful in the treatment or prevention of autoimmune diseases, particularly rheumatoid arthritis, asthma, allergies, and host versus graft (or graft versus host) rejection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AX-158
Therapeutic Area: Immunology Product Name: AX-158
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
U.S. Patent covers AX-158, certain additional backup compounds, and pharmaceutical compositions thereof, and is expected to expire no earlier than 2039 in the United States.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tolimidone
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania’s COVID-19 Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 15, 2020
Details:
The Phase 2 clinical trial is intended to test tolimidone in subjects who were recently diagnosed with COVID19, but are not hospitalized. Tolimidone is expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VB-601
Therapeutic Area: Immunology Product Name: VB-601
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
VB-601 is the Company’s lead anti-MOSPD2 antibody for immune-inflammatory indications, for which a briefing package for the pre-IND meeting was submitted in June. Based on the FDA's feedback, VBL plans to advance its IND-enabling activities for VB-601 as planned.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amilo-5MER
Therapeutic Area: Immunology Product Name: Amilo-5MER
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Hebrew University of Jerusalem
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
The 5 amino acids sequence of Amilo-5MER is homologue to a specific MTADV sequence in the human CD44 variant found in synovial fluid cells from joints of rheumatoid arthritis (RA) patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SDC-1802
Therapeutic Area: Immunology Product Name: SDC-1802
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ILB-202
Therapeutic Area: Immunology Product Name: ILB-202
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
This latest patent is integral to the Company's EXPLOR® platform technology as well as the Exo-Target® products, as the patent covers not only EXPLOR® technology but also its application for various therapeutic cargo proteins developed by ILIAS for loading into exosomes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CIT-013
Therapeutic Area: Immunology Product Name: CIT-013
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: BOM Brabant Ventures
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 02, 2020
Details:
The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
